Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Greenberg

Showing results (51-60 of 93) with videos related to

Pageof 10
Sort By:
Blood|December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaMitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.
Leukemia Research|June 3, 2017
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]Ronan T Swords, Peter L Greenberg, Andrew H Wei, et al.
The EMBO Journal|February 15, 2024
Shared and distinct mechanisms of UBA1 inactivation across different diseasesJason C Collins, Samuel J Magaziner, Maya English, et al.
Journal of Hematology & Oncology|June 28, 2017
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Biorxiv : the Preprint Server for Biology|October 24, 2023
Shared and Distinct Mechanisms of UBA1 Inactivation Across Different DiseasesJason C Collins, Samuel J Magaziner, Maya English, et al.
Leukemia Research|October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 studyRonan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2007
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Blood|June 23, 2012
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDSLaura Barreyro, Britta Will, Boris Bartholdy, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 1, 2005
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Blood|July 7, 2022
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblastsAmer M Zeidan, Uwe Platzbecker, Guillermo Garcia-Manero, et al.
Pageof 10

Showing results (51-60 of 93) with videos related to

Sort By:
Pageof 10
Blood|December 28, 2007
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemiaMitch Raponi, Jeffrey E Lancet, Hongtao Fan, et al.
Leukemia Research|June 3, 2017
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729]Ronan T Swords, Peter L Greenberg, Andrew H Wei, et al.
The EMBO Journal|February 15, 2024
Shared and distinct mechanisms of UBA1 inactivation across different diseasesJason C Collins, Samuel J Magaziner, Maya English, et al.
Journal of Hematology & Oncology|June 28, 2017
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag, et al.
Biorxiv : the Preprint Server for Biology|October 24, 2023
Shared and Distinct Mechanisms of UBA1 Inactivation Across Different DiseasesJason C Collins, Samuel J Magaziner, Maya English, et al.
Leukemia Research|October 14, 2016
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 studyRonan T Swords, Peter L Greenberg, Andrew H Wei, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 19, 2007
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Blood|June 23, 2012
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDSLaura Barreyro, Britta Will, Boris Bartholdy, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 1, 2005
Chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Kapil Bhalla, et al.
Blood|July 7, 2022
Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblastsAmer M Zeidan, Uwe Platzbecker, Guillermo Garcia-Manero, et al.
Pageof 10